Drugs / MMRvaxpro
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | M-M-RVaxPro | — | 2006-05-05 | europa.eu ↗ |
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT05894395 | Dec 2023 → Mar 2025 | measles, mumps infectious disease, rubella | University of Zurich | Unknown | No outcome recorded |
| Phase 41 trial · 1 missed | ||||||
| Phase 4 | NCT03780179 | Apr 2019 → Jan 2022 | primary viral infectious disease | Rigshospitalet, Denmark | Completed | Missed primary |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT06975878 Background | May 2025 → Aug 2027 expected | — | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01839175 Background | Apr 2013 → Jul 2014 | meningococcal infection, viral infectious disease | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MMRvaxpro | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03780179 ↗ |
| Modality | Vaccine | “Measles, mumps and rubella vaccine (live)” NCT01839175 ↗ |
| Route | Intramuscular | “0.5 mL intramuscular or subcutaneous injection at 13 months of age” NCT01839175 ↗ |
| Route | Subcutaneous | “0.5 mL intramuscular or subcutaneous injection at 13 months of age” NCT01839175 ↗ |